ArticleJournal of inflammation research2025
Long Non-Coding RNA EPB41L4A-AS1 Serves as a Diagnostic Marker for Chronic Periodontitis and Regulates Periodontal Ligament Injury and Osteogenic Differentiation by Targeting miR-214-3p/YAP1.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Non-Coding RNAs in Oral Diseases: From Pathogenesis to Clinical Translation.International journal of molecular sciences · 2026Review
- Neuroprotective Effects of lncRNA EPB41L4A-AS1 Against Ischemic Stroke Injury Through Regulating Microglial State Transition and Ferroptosis via miR-214-3p/GPX4 Axis.Neurochemical research · 2026Article
- YAP1 in control: how RNA networks and protein modifications shape its function and therapeutic targetability.Molecular cancer · 2026Review
- LncRNA FAM30A as a potential biomarker associated with periodontitis and its role in inflammatory responses and osteogenesis.BMC oral health · 2026Article
- Noncoding RNAs in periodontitis: Progress and perspectives (Review).International journal of molecular medicine · 2025Review
- Long non-coding RNA EPB41L4A-AS1 as a biomarker of sepsis alleviates inflammatory response by targeting miR-146a-5p.European journal of medical research · 2025Article
- Ginkgolide B Alleviates LPS-Induced Inhibition of Osteogenic Differentiation in Human Periodontal Ligament Stem Cells by Suppressing the p-IκBα/NF-κB Pathway.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Several long non-coding RNAs (lncRNAs) are dysregulated in chronic periodontitis (CP). Purpose: The study aimed to elucidate the molecular mechanisms and clinical significance of lncRNA EPB41L4A antisense RNA 1 (EPB41L4A-AS1) in CP. Patients and Methods: This study enrolled 101 patients with CP and 90 subjects with healthy periodontal tissues. Patients with CP were categorized according to severity. The expression of EPB41L4A-AS1 and osteogenic markers in the lipopolysaccharide (LPS)-induced human periodontal ligament cells (hPDLCs) was assessed using real-time quantitative reverse transcription PCR (RT-qPCR). The diagnostic significance of EPB41L4A-AS1 was evaluated using receiver operating characteristic (ROC) analysis. The levels of inflammatory factors were measured using an enzyme-linked immunosorbent assay. Cell proliferation and apoptosis were analyzed using cell counting kit -8 and flow cytometry, respectively. The interaction between EPB41L4A-AS1 and microRNAs was verified using dual luciferase reporter assays, RNA immunoprecipitation, and RNA pull-down assays. Results: EPB41L4A-AS1 was downregulated in the gingival sulcus fluid of patients with CP and LPS-induced hPDLCs. Additionally, EPB41L4A-AS1 could distinguish patients with CP from control subjects with sensitivity (88.12%) and specificity (81.11%). The expression of EPB41L4A-AS1 was downregulated in patients with severe CP. EPB41L4A-AS1 downregulation was directly correlated with severe clinical indicators and inversely correlated with inflammatory indicators. The overexpression of EPB41L4A-AS1 promoted the proliferation and osteogenic differentiation of hPDLCs and mitigated LPS-induced inflammation. Mechanistically, EPB41L4A-AS1 directly targets and downregulates miR-214-3p expression, resulting in the upregulation of Yes1-associated transcriptional regulator (YAP1) levels. The overexpression of miR-214-3p partially suppressed the effects of EPB41L4A-AS1 on LPS-induced hPDLC injury and osteogenic differentiation. Conclusion: The overexpression of EPB41L4A-AS1 suppressed LPS-induced hPDLC injury and enhanced osteogenic differentiation through the miR-214-3p/YAP1 axis. Thus, EPB41L4A-AS1 is a novel diagnostic marker and a therapeutic target for CP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.